share_log

UPLOAD: Others

UPLOAD: Others

UPLOAD:其他
美股SEC公告 ·  2024/04/17 22:16

Moomoo AI 已提取核心信息

Adial Pharmaceuticals, Inc. has been informed by the United States Securities and Exchange Commission (SEC) that its registration statement on Form S-3, filed on April 12, 2024, will not undergo review by the commission. The SEC's communication, dated April 17, 2024, was addressed to Cary Claiborne, the Chief Executive Officer of Adial Pharmaceuticals. The SEC's letter also referenced Rules 460 and 461, which pertain to requests for acceleration of the registration process. The SEC reminded the company and its management of their responsibility to ensure the accuracy and adequacy of their disclosures, regardless of the SEC's level of review or lack thereof. For further inquiries, the SEC has provided contact information for Lauren Hamill.
Adial Pharmaceuticals, Inc. has been informed by the United States Securities and Exchange Commission (SEC) that its registration statement on Form S-3, filed on April 12, 2024, will not undergo review by the commission. The SEC's communication, dated April 17, 2024, was addressed to Cary Claiborne, the Chief Executive Officer of Adial Pharmaceuticals. The SEC's letter also referenced Rules 460 and 461, which pertain to requests for acceleration of the registration process. The SEC reminded the company and its management of their responsibility to ensure the accuracy and adequacy of their disclosures, regardless of the SEC's level of review or lack thereof. For further inquiries, the SEC has provided contact information for Lauren Hamill.
美国证券交易委员会(SEC)已告知Adial Pharmicals, Inc.,其于2024年4月12日提交的S-3表格的注册声明将不接受该委员会的审查。美国证券交易委员会于2024年4月17日致阿迪尔制药公司首席执行官卡里·克莱伯恩的信函。美国证券交易委员会的信中还提到了与加快注册程序的请求有关的第460和461条。美国证券交易委员会提醒该公司及其管理层,无论美国证券交易委员会的审查水平如何,他们都有责任确保披露的准确性和充分性。为了进一步调查,美国证券交易委员会提供了劳伦·哈米尔的联系信息。
美国证券交易委员会(SEC)已告知Adial Pharmicals, Inc.,其于2024年4月12日提交的S-3表格的注册声明将不接受该委员会的审查。美国证券交易委员会于2024年4月17日致阿迪尔制药公司首席执行官卡里·克莱伯恩的信函。美国证券交易委员会的信中还提到了与加快注册程序的请求有关的第460和461条。美国证券交易委员会提醒该公司及其管理层,无论美国证券交易委员会的审查水平如何,他们都有责任确保披露的准确性和充分性。为了进一步调查,美国证券交易委员会提供了劳伦·哈米尔的联系信息。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息